Hydroxyprogesterone caproate - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for hydroxyprogesterone caproate and what is the scope of freedom to operate?
Hydroxyprogesterone caproate
is the generic ingredient in two branded drugs marketed by Allergan, Epic Pharma Llc, Bristol Myers Squibb, Aspen Global Inc, and Eugia Pharma, and is included in six NDAs. Additional information is available in the individual branded drug profile pages.There are ten drug master file entries for hydroxyprogesterone caproate. One supplier is listed for this compound.
Summary for hydroxyprogesterone caproate
US Patents: | 0 |
Tradenames: | 2 |
Applicants: | 5 |
NDAs: | 6 |
Drug Master File Entries: | 10 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 73 |
Clinical Trials: | 30 |
Patent Applications: | 7,082 |
Drug Prices: | Drug price trends for hydroxyprogesterone caproate |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for hydroxyprogesterone caproate |
What excipients (inactive ingredients) are in hydroxyprogesterone caproate? | hydroxyprogesterone caproate excipients list |
DailyMed Link: | hydroxyprogesterone caproate at DailyMed |
Recent Clinical Trials for hydroxyprogesterone caproate
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Bezmialem Vakif University | N/A |
Assiut University | Phase 4 |
Aswan University Hospital | N/A |
Pharmacology for hydroxyprogesterone caproate
Drug Class | Progestin |
Anatomical Therapeutic Chemical (ATC) Classes for hydroxyprogesterone caproate
Paragraph IV (Patent) Challenges for HYDROXYPROGESTERONE CAPROATE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
MAKENA (AUTOINJECTOR) | Injection (Auto- injector) | hydroxyprogesterone caproate | 275 mg/1.1 mL | 021945 | 1 | 2020-09-28 |
US Patents and Regulatory Information for hydroxyprogesterone caproate
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bristol Myers Squibb | DELALUTIN | hydroxyprogesterone caproate | SOLUTION;INTRAMUSCULAR | 010347-004 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Allergan | HYDROXYPROGESTERONE CAPROATE | hydroxyprogesterone caproate | INJECTABLE;INJECTION | 017439-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Bristol Myers Squibb | DELALUTIN | hydroxyprogesterone caproate | SOLUTION;INTRAMUSCULAR | 010347-002 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.